Drugs / MAG200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07106229 | Nov 2025 → Feb 2028 expected | osteoarthritis, knee | Magellan Stem Cells | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAG200 | “The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs).” NCT07106229 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived mesenchymal stem cell preparation” NCT07106229 ↗ |